Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma

Akihiro Hirakawa, Tadaaki Nishikawa, Kan Yonemori, Taro Shibata, Kenichi Nakamura, Masashi Ando, Takafumi Ueda, Toshihumi Ozaki, Kenji Tamura, Akira Kawai, Yasuhiro Fujiwara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Investigational drugs for rare cancers are often approved based solely on a single-arm phase II trial that primarily evaluates response rate in Japan. Such trials typically use a fixed sample size determined on the basis of the frequentist manner. However, since predicting the speed of patient enrollment is challenging because of the disease rarity, the time needed to complete the enrollment of the fixed number of patients is prolonged in some cases. A Bayesian design without fixing the sample size is useful for single-arm phase II trials of rare cancers. However, the arbitrariness of prior distribution specifications and the frequentist operating characteristics are regulatory issues. We recently started a Bayesian single-arm phase II trial of nivolumab in patients with sarcoma for new drug application in Japan and examined the statistical rationale and design consideration. In the Bayesian design, we specify the minimum and maximum numbers of enrolled patients during the enrollment period and the prior distributions of response rates. Considering these parameters, we obtain the minimum number of responders needed for the positive conclusion of the efficacy of nivolumab for each sample size. Simulation studies demonstrated that the operating characteristics of this design would be acceptable from the frequentist view. The Bayesian design provided an adaptive decision rule for efficacy conclusion for the drug without fixing the sample size. We hope our trial’s success will provide a new drug development option for rare cancers in Japan.

Original languageEnglish
Pages (from-to)334-338
Number of pages5
JournalTherapeutic Innovation and Regulatory Science
Volume52
Issue number3
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Sarcoma
Sample Size
Japan
Pharmaceutical Preparations
Neoplasms
Investigational Drugs
nivolumab

Keywords

  • Bayesian design
  • rare cancer
  • single-arm trial

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan : A Case Study of Phase 2 Trial for Sarcoma. / Hirakawa, Akihiro; Nishikawa, Tadaaki; Yonemori, Kan; Shibata, Taro; Nakamura, Kenichi; Ando, Masashi; Ueda, Takafumi; Ozaki, Toshihumi; Tamura, Kenji; Kawai, Akira; Fujiwara, Yasuhiro.

In: Therapeutic Innovation and Regulatory Science, Vol. 52, No. 3, 01.05.2018, p. 334-338.

Research output: Contribution to journalArticle

Hirakawa, A, Nishikawa, T, Yonemori, K, Shibata, T, Nakamura, K, Ando, M, Ueda, T, Ozaki, T, Tamura, K, Kawai, A & Fujiwara, Y 2018, 'Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma', Therapeutic Innovation and Regulatory Science, vol. 52, no. 3, pp. 334-338. https://doi.org/10.1177/2168479017728989
Hirakawa, Akihiro ; Nishikawa, Tadaaki ; Yonemori, Kan ; Shibata, Taro ; Nakamura, Kenichi ; Ando, Masashi ; Ueda, Takafumi ; Ozaki, Toshihumi ; Tamura, Kenji ; Kawai, Akira ; Fujiwara, Yasuhiro. / Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan : A Case Study of Phase 2 Trial for Sarcoma. In: Therapeutic Innovation and Regulatory Science. 2018 ; Vol. 52, No. 3. pp. 334-338.
@article{352cccd7fe03435bb82a19f985749d20,
title = "Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma",
abstract = "Investigational drugs for rare cancers are often approved based solely on a single-arm phase II trial that primarily evaluates response rate in Japan. Such trials typically use a fixed sample size determined on the basis of the frequentist manner. However, since predicting the speed of patient enrollment is challenging because of the disease rarity, the time needed to complete the enrollment of the fixed number of patients is prolonged in some cases. A Bayesian design without fixing the sample size is useful for single-arm phase II trials of rare cancers. However, the arbitrariness of prior distribution specifications and the frequentist operating characteristics are regulatory issues. We recently started a Bayesian single-arm phase II trial of nivolumab in patients with sarcoma for new drug application in Japan and examined the statistical rationale and design consideration. In the Bayesian design, we specify the minimum and maximum numbers of enrolled patients during the enrollment period and the prior distributions of response rates. Considering these parameters, we obtain the minimum number of responders needed for the positive conclusion of the efficacy of nivolumab for each sample size. Simulation studies demonstrated that the operating characteristics of this design would be acceptable from the frequentist view. The Bayesian design provided an adaptive decision rule for efficacy conclusion for the drug without fixing the sample size. We hope our trial’s success will provide a new drug development option for rare cancers in Japan.",
keywords = "Bayesian design, rare cancer, single-arm trial",
author = "Akihiro Hirakawa and Tadaaki Nishikawa and Kan Yonemori and Taro Shibata and Kenichi Nakamura and Masashi Ando and Takafumi Ueda and Toshihumi Ozaki and Kenji Tamura and Akira Kawai and Yasuhiro Fujiwara",
year = "2018",
month = "5",
day = "1",
doi = "10.1177/2168479017728989",
language = "English",
volume = "52",
pages = "334--338",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan

T2 - A Case Study of Phase 2 Trial for Sarcoma

AU - Hirakawa, Akihiro

AU - Nishikawa, Tadaaki

AU - Yonemori, Kan

AU - Shibata, Taro

AU - Nakamura, Kenichi

AU - Ando, Masashi

AU - Ueda, Takafumi

AU - Ozaki, Toshihumi

AU - Tamura, Kenji

AU - Kawai, Akira

AU - Fujiwara, Yasuhiro

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Investigational drugs for rare cancers are often approved based solely on a single-arm phase II trial that primarily evaluates response rate in Japan. Such trials typically use a fixed sample size determined on the basis of the frequentist manner. However, since predicting the speed of patient enrollment is challenging because of the disease rarity, the time needed to complete the enrollment of the fixed number of patients is prolonged in some cases. A Bayesian design without fixing the sample size is useful for single-arm phase II trials of rare cancers. However, the arbitrariness of prior distribution specifications and the frequentist operating characteristics are regulatory issues. We recently started a Bayesian single-arm phase II trial of nivolumab in patients with sarcoma for new drug application in Japan and examined the statistical rationale and design consideration. In the Bayesian design, we specify the minimum and maximum numbers of enrolled patients during the enrollment period and the prior distributions of response rates. Considering these parameters, we obtain the minimum number of responders needed for the positive conclusion of the efficacy of nivolumab for each sample size. Simulation studies demonstrated that the operating characteristics of this design would be acceptable from the frequentist view. The Bayesian design provided an adaptive decision rule for efficacy conclusion for the drug without fixing the sample size. We hope our trial’s success will provide a new drug development option for rare cancers in Japan.

AB - Investigational drugs for rare cancers are often approved based solely on a single-arm phase II trial that primarily evaluates response rate in Japan. Such trials typically use a fixed sample size determined on the basis of the frequentist manner. However, since predicting the speed of patient enrollment is challenging because of the disease rarity, the time needed to complete the enrollment of the fixed number of patients is prolonged in some cases. A Bayesian design without fixing the sample size is useful for single-arm phase II trials of rare cancers. However, the arbitrariness of prior distribution specifications and the frequentist operating characteristics are regulatory issues. We recently started a Bayesian single-arm phase II trial of nivolumab in patients with sarcoma for new drug application in Japan and examined the statistical rationale and design consideration. In the Bayesian design, we specify the minimum and maximum numbers of enrolled patients during the enrollment period and the prior distributions of response rates. Considering these parameters, we obtain the minimum number of responders needed for the positive conclusion of the efficacy of nivolumab for each sample size. Simulation studies demonstrated that the operating characteristics of this design would be acceptable from the frequentist view. The Bayesian design provided an adaptive decision rule for efficacy conclusion for the drug without fixing the sample size. We hope our trial’s success will provide a new drug development option for rare cancers in Japan.

KW - Bayesian design

KW - rare cancer

KW - single-arm trial

UR - http://www.scopus.com/inward/record.url?scp=85042348654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042348654&partnerID=8YFLogxK

U2 - 10.1177/2168479017728989

DO - 10.1177/2168479017728989

M3 - Article

C2 - 29714533

AN - SCOPUS:85042348654

VL - 52

SP - 334

EP - 338

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

IS - 3

ER -